Active Biotech AB Interim report January - September 2014

November 5, 2014 08:34 (CET)

LUND, Sweden, Nov. 5, 2014 (GLOBE NEWSWIRE) -- Laquinimod
· Teva presented new clinical safety data in RRMS patients treated with laquinimod for two or more years at joint ACTRIMS-ECTRIMS meeting
· Teva initiated clinical studies with laquinimod in primary progressive MS (PPMS) and Huntington's disease
· The ongoing US pivotal clinical study CONCERTO is continuing according to plan. Results are expected in the first half of 2016

Tasquinimod     
· The Phase III study 10TASQ10 is proceeding according to the original schedule and results are expected in the first half of 2015

ANYARA
· Only out-licensing activities are being conducted
                    
Paquinimod (57-57)  
· Only out-licensing activities are being conducted

ISI
· CD selection expected in 2015.

New share issue
· Rights issue totaling approximately SEK 225 million to be approved by the Extraordinary General Meeting on December 1, 2014

Financial summary

MSEKJuly - Sept. January - Sept. Full Year
 20142013 20142013 2013
        
Net sales2.6107.0 7.5111.9 116.0
        
Operating loss-55.727.9 -172.8-128.6 -209.0
        
Loss for the period-56.629.2 -174.5-130.0 -212.1
        
Loss per share (SEK)-0.760.39 -2.33-1.77 -2.87
(before and after dilution)       

 

For further information, please contact:

Tomas Leanderson, President and CEO
 Tel: +46 (0)46 19 20 95
 
Hans Kolam, CFO
Tel: +46 (0)46 19 20 44
 
Active Biotech AB
(Corp. Reg. No. 556223-9227)
Box 724, SE-220 07 Lund
Tel: +46 (0)46 19 20 00
Fax: +46 (0)46 19 11 00

The report is also available at www.activebiotech.com

 

Active Biotech AB Interim report January - September 2014 http://hugin.info/1002/R/1868647/656843.pdf

HUG#1868647